Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Purdue Pharma L p
Purdue Pharma L p_20100107
Purdue Pharma L p_20100128
  

Purdue Pharma L p patents

Recent patent applications related to Purdue Pharma L p. Purdue Pharma L p is listed as an Agent/Assignee. Note: Purdue Pharma L p may have other listings under different names/spellings. We're not affiliated with Purdue Pharma L p, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "P" | Purdue Pharma L p-related inventors




Date Purdue Pharma L p patents (updated weekly) - BOOKMARK this page
10/19/17 new patent  Pharmaceutical formulation containing gelling agent
10/19/17 new patent  Tamper resistant pharmaceutical formulations
10/19/17 new patent  Pyrimidines as sodium channel blockers
10/12/17Benzomorphan analogs and the use thereof
10/05/17Dibenzazepine derivatives and use thereof
08/31/17Tamper resistant dosage forms
08/31/17Acetaminophen-containing analgesic formulations with reduced hepatotoxicity
08/17/17Matrix for sustained, invariant and independent release of active compounds
08/17/17Methods for making 3-o-protected morphinones and 3-o-protected morphinone dienol carboxylates
08/10/17Transdermal therapeutic system for administering the active substance buprenorphine
08/03/17Tamper resistant pharmaceutical formulations
07/27/17Pyrimidine carboxamides as sodium channel blockers
07/20/177-beta-alkyl analogs of orvinols
07/06/17Spirocyclic morphinans and use thereof
06/29/17Trpv1 antagonists including dihydroxy substituent and uses thereof
06/22/17Pharmaceutical formulation containing irritant
06/08/17Buprenorphine-wafer for drug substitution therapy
06/08/17Abuse resistant opioid transdermal delivery device containing opioid antagonist microspheres
06/08/17Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
06/01/17Methods of manufacturing oral formulations
05/25/17Methods of providing analgesia
05/18/17Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
05/18/17Methods of treating opiate dependency and preventing non-oral opiate abuse among opiate addicts
05/18/17Methods of manufacturing oral dosage forms
05/11/17Tamper resistant dosage forms
05/11/17Tamper resistant dosage forms
05/11/17Tamper resistant dosage forms
05/11/17Tamper resistant dosage forms
05/11/17Tamper resistant dosage forms
05/11/17Tamper resistant dosage forms
05/11/17Tamper resistant dosage forms
05/11/17Buprenorphine transdermal delivery system
05/11/17Tamper resistant dosage forms
05/04/17Tamper resistant oral opioid agonist formulations
05/04/17Pharmaceutical formulation containing irritant
04/27/17Pharmaceutical formulation containing gelling agent
04/27/17Pharmaceutical preparation containing oxycodone and naloxone
04/20/17Crystalline forms of tyrosine kinase inhibitors and their salts
04/20/17Azamorphinan derivatives and use thereof
04/13/17Naltrexone hydrochloride compositions
04/06/17Carboxamide derivatives and use thereof
03/30/17Controlled release hydrocodone formulations
03/30/17Methods of providing analgesia
03/30/17Controlled release hydrocodone formulations
03/23/17Alcohol resistant dosage forms
03/16/17Benzomorphan analogs and use thereof
03/09/17Pharmaceutical formulation containing gelling agent
03/09/17Pharmaceutical formulation containing gelling agent
03/09/17Pharmaceutical dosage forms
03/02/17Method of providing sustained analgesia with buprenorphine
03/02/17Isoquinoline derivatives and use thereof
02/23/17Transdermal delivery system comprising buprenorphine
02/09/1710-substituted morphinan hydantoins
01/26/17Tamper resistant solid oral dosage forms
01/26/17Pharmaceutical formulation containing gelling agent
01/26/17Pharmaceutical formulation containing gelling agent
01/26/17Opioid agonist/opioid antagonist/acetaminophen combinations
01/19/17Abuse-resistant controlled-release opioid dosage form
01/19/17Abuse-resistant controlled-release opioid dosage form
01/12/17Pyridines and pyrimidines and use thereof
01/05/17Indazoles and use thereof
01/05/17Crystalline forms of tyrosine kinase inhibitors and their salts
12/08/16Trpv1 antagonists including dihydroxy substituent and uses thereof
11/24/16Ring-contracted morphinans and the use thereof
11/17/16Pyrimidines and use thereof
Patent Packs
11/17/167-beta analogs of orvinols
11/10/16Aryl substituted indoles and the use thereof
11/03/16Pharmaceutical compositions
11/03/166-substituted and 7-substituted morphinan analogs and the use thereof
11/03/16Trpv1 antagonists including dihydroxy substituent and uses thereof
11/03/16Pyridone-sulfone morphinan analogs as opioid receptor ligands
10/27/16Acrylic polymer formulations
09/15/16Abuse-resistant controlled-release opioid dosage form
09/15/16Process for preparing oxycodone compositions
09/08/16Abuse-resistant controlled-release opioid dosage form
09/01/16Process for preparing oxycodone compositions
09/01/16Process for preparing oxycodone compositions
09/01/16Process for preparing oxycodone compositions
09/01/16Process for preparing oxycodone compositions
09/01/16Process for preparing oxycodone compositions
Patent Packs
08/25/16Opioid antagonist formulations
08/25/16Encased tamper resistant controlled release dosage forms
08/25/16Encased tamper resistant controlled release dosage forms
08/25/16Encased tamper resistant controlled release dosage forms
08/25/16Methods and compositions for decreasing gastric emptying
08/18/16Buprenorphine-wafer for drug substitution therapy
08/18/16Buprenorphine wafer for drug substitution therapy
08/11/16Controlled release hydrocodone formulations
08/04/16Method of providing sustained analgesia with buprenorphine
08/04/16Trpv1 antagonists including dihydroxy substituent and uses thereof
08/04/16Analogs of sodium channel peptide toxin
07/21/16Azaspiro[4.5] decane derivatives and use thereof
06/30/16Process for preparing oxycodone compositions
06/30/16Process for preparing oxycodone compositions
06/30/16Process for preparing oxycodone compositions
06/23/16Oxycodone dosage forms
06/23/16Methods of treating pain
06/23/16Process for preparing oxycodone docage form
06/23/16Transdermal therapeutic system for administering the active substance buprenorphine
06/23/16Process for preparing oxycodone compositions
06/23/16Process for preparing oxycodone compositions
06/09/16Encased tamper resistant controlled release dosage forms
06/09/16Controlled release hydrocodone formulations
06/09/16Controlled release hydrocodone formulations
06/09/16Substituted-quinoxaline-type piperidine compounds and the uses thereof
06/02/16Pharmaceutical formulation containing gelling agent
06/02/16Controlled release hydrocodone formulations
06/02/16Pharmaceutical formulation containing gelling agent
06/02/16Pharmaceutical formulation containing gelling agent
06/02/16Pharmaceutical formulation containing gelling agent
Social Network Patent Pack
06/02/16Controlled release hydrocodone formulations
06/02/16Pharmaceutical formulation containing gelling agent
06/02/16Abuse-resistant controlled-release opioid dosage form
06/02/16Abuse-resistant controlled-release opioid dosage form
06/02/16Pharmaceutical formulation containing gelling agent
06/02/16Pharmaceutical formulation containing gelling agent
06/02/16Pharmaceutical formulation containing gelling agent
06/02/16Pharmaceutical formulation containing gelling agent
06/02/16Pharmaceutical formulation containing gelling agent
06/02/16Controlled release hydrocodone formulations
Patent Packs
06/02/16Pharmaceutical formulation containing gelling agent
06/02/16Pharmaceutical formulation containing gelling agent
05/26/16Tamper resistant oral dosage forms
05/26/16Substituted pyridines as sodium channel blockers
05/19/16Immediate release pharmaceutical compositions comprising oxycodone and naloxone
05/05/16Methods of preparing tamper resistant solid oral dosage forms
05/05/16Transdermal delivery system comprising buprenorphine
05/05/16Compositions and methods for treating an arrhythmia with an opioid antagonist
04/21/16Systems and methods for treating an opioid-induced adverse pharmacodynamic response
04/14/16Transdermal delivery system
04/07/16Use of binders for manufacturing storage stable formulations
03/17/16Systems and methods for attenuating opioid-induced euphoria
02/25/16Opioid agonist/antagonist combinations
02/25/16Heteroaryl compounds as sodium channel blockers
02/11/16Tamper resistant pharmaceutical formulations
02/04/16Once-a-day oxycodone formulations
02/04/16Carboxamide derivatives and use thereof
01/28/16Pyrimidines as sodium channel blockers
01/28/16Peptide immunogens
01/28/16Pyrimidines as sodium channel blockers
01/14/16Transdermal delivery system
01/14/16Abuse-resistant controlled-release opioid dosage form
01/14/16Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
01/14/16Abuse-resistant controlled-release opioid dosage form
01/14/16Systems and methods to quantify analytes in keratinized samples
01/14/16Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
01/07/16Pharmaceutical formulation containing gelling agent
01/07/16Pharmaceutical formulation containing gelling agent
01/07/16Pharmaceutical formulation containing gelling agent
01/07/16Pharmaceutical formulation containing gelling agent
Patent Packs
01/07/16Pharmaceutical formulation containing gelling agent
01/07/16Pharmaceutical formulation containing gelling agent
01/07/16Quinazolin-4(3h)-one-type piperidine compounds and uses thereof
12/31/15Pharmaceutical formulation containing gelling agent
12/31/15Pharmaceutical formulation containing gelling agent
12/24/15Pharmaceutical products
12/24/15Pharmaceutical formulation containing irritant
12/10/15Triazine carboxamides as sodium channel blockers
12/03/15Pyridine compounds as sodium channel blockers
11/26/15Tamper resistant dosage forms
11/26/15Tamper resistant dosage forms
11/26/15Tamper resistant dosage forms
11/26/15Tamper resistant dosage forms
11/26/15Pyrimidine diol amides as sodium channel blockers
11/26/15Cyclic sulfonamides as sodium channel blockers
11/19/15Buprenorphine-wafer for drug substitution therapy
11/12/15Substituted benzimidazole-type piperidine compounds and uses thereof
10/29/15Transdermal delivery system
10/08/15Pharmaceutical formulation containing gelling agent
10/08/15Pharmaceutical formulation containing gelling agent
Social Network Patent Pack
10/08/15Pharmaceutical formulation containing gelling agent
10/08/15Pharmaceutical formulation containing gelling agent
10/08/15Indole derivatives and use thereof
10/01/15Pharmaceutical formulation containing gelling agent
10/01/15Pharmaceutical formulation containing gelling agent
09/24/15Pharmaceutical dosage forms comprising poly(epsilon-caprolactone) and polyethylene oxide
09/24/15Controlled release hydrocodone formulations
09/24/15Oxycodone compositions
09/24/15Oxycodone compositions
09/24/15Tamper resistant dosage forms
09/24/15Pharmaceutical formulation containing gelling agent
09/24/15Pharmaceutical formulation containing gelling agent
09/24/15Pharmaceutical formulation containing gelling agent
09/24/15Pharmaceutical formulation containing gelling agent
09/24/15Pharmaceutical formulation containing gelling agent
09/24/15Pharmaceutical formulation containing gelling agent
09/17/15Pyridine compounds and the uses thereof
09/17/15Oxycodone compositions
09/17/15Abuse-resistant controlled-release opioid dosage form
09/17/15Abuse-resistant controlled-release opioid dosage form
Social Network Patent Pack
09/17/15Controlled release hydrocodone formulations
09/17/15Controlled release hydrocodone formulations
09/10/15Quinazoline compounds as sodium channel blockers
08/27/15Controlled release hydrocodone formulations
08/27/15Pharmaceutical formulation containing gelling agent
08/27/15Oxime-substituted quinoxaline-type piperidine compounds as orl-1 modulators
08/27/15Methods for making 3-o-protected morphinones and 3-o-protected morphinone dienol carboxylates
08/20/15Tamper-resistant oral opioid agonist formulations
08/20/15Once-a-day oxycodone formulations
08/06/15Controlled release hydrocodone formulations
08/06/15Controlled release hydrocodone formulations
08/06/15Systems and methods for treating an opioid-induced adverse pharmacodynamic response
07/30/15Benzomorphan compounds as opioid receptors modulators
07/23/15Tamper resistant pharmaceutical formulations
07/23/15Pyridonemorphinan analogs and biological activity on opioid receptors
07/23/15Spirocyclic morphinans and their use
07/23/15Buprenorphine analogs
07/16/15Systems and methods for treating an opioid-induced adverse pharmacodynamic response
07/16/15Systems and methods for treating an opioid-induced adverse pharmacodynamic response
07/16/15Systems and methods for treating an opioid-induced adverse pharmacodynamic response
07/16/15Systems and methods for treating an opioid-induced adverse pharmacodynamic response
07/16/15Systems and methods for treating an opioid-induced adverse pharmacodynamic response
07/16/15Tamper resistant pharmaceutical formulations
07/16/15Tamper resistant pharmaceutical formulations
07/16/15Tamper resistant pharmaceutical formulations
07/09/15Use of oxycodone for treating visceral pain
07/09/15Novel sodium channel blocking peptides and the use thereof
07/02/15Tamper-resistant oral opioid agonist formulations
07/02/15Disposal system for transdermal dosage form
07/02/15Pharmaceutical formulation containing gelling agent
Social Network Patent Pack
07/02/15Propellane-based compounds and the use thereof
06/25/15Controlled release hydrocodone formulations
06/25/15Dibenzazepine derivatives and use thereof
06/25/15Substituted morphinans and the use thereof
06/18/15Systems and methods for treating an opioid-induced adverse pharmacodynamic response
06/11/15Method of providing sustained analgesia with buprenorphine
05/28/15Pharmaceutical formulation containing gelling agent
05/28/15Pharmaceutical formulation containing gelling agent
05/28/15Controlled release hydrocodone formulations
05/21/15Pharmaceutical formulation containing gelling agent
05/21/15Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
05/21/15Once-a-day oxycodone formulations
05/21/15Pyridine and piperidine derivatives and use thereof
05/21/15Substituted-quinoxaline-type piperidine compounds and the uses thereof
05/14/15Benzimidazole derivatives and use thereof
04/23/15Controlled release hydrocodone formulations
04/23/15Opioid agonist formulations with releasable and sequestered antagonist
04/02/15Systems and methods for treating an opioid-induced adverse pharmacodynamic response
04/02/15Antibodies that bind cell-associated ca 125/o772p
03/19/15Pharmaceutical combinations of hydrocodone and naltrexone
02/26/15Substituted piperidines as sodium channel blockers
02/12/15Substituted pyridines as sodium channel blockers
02/05/15Controlled release hydrocodone formulations
02/05/15Tamper resistant dosage forms
02/05/15Tamper resistant dosage forms
02/05/15Tamper resistant dosage forms
01/29/15Tamper resistant dosage forms
01/29/15Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
01/22/15Opioid agonist/antagonist combinations







ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Purdue Pharma L p in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Purdue Pharma L p with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';